Saltar al contenido
Merck
Todas las fotos(2)

Documentos clave

SAB4200772

Sigma-Aldrich

Anti-BRAF (V600E) antibody produced in rabbit

enhanced validation

affinity isolated antibody

Sinónimos:

Anti-Proto-oncogene B-Raf, p94, Anti-Serine/threonine-protein kinase B-raf, Anti-v-Raf murine sarcoma viral oncogene homolog B1

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(2)

About This Item

Código UNSPSC:
12352203
NACRES:
NA.44

origen biológico

rabbit

Nivel de calidad

200

forma del anticuerpo

affinity isolated antibody

tipo de anticuerpo

primary antibodies

clon

polyclonal

Formulario

buffered aqueous solution

mol peso

~95 kDa

reactividad de especies

human

validación mejorada

recombinant expression
Learn more about Antibody Enhanced Validation

concentración

~1 mg/mL

técnicas

immunoblotting: 2-4 μg/mL using extract of human HEK-293T cells over-expressing BRAF mutant (V600E) protein

Nº de acceso UniProt

P15056

Condiciones de envío

dry ice

temp. de almacenamiento

−20°C

modificación del objetivo postraduccional

unmodified

Información sobre el gen

human ... BRAF(673)

Descripción general

B-Raf proto-oncogene serine/threonine-protein kinase (BRAF), also known as Serine/threonine-protein kinase B-raf, Proto-oncogene B-Raf, p94, v-Raf murine sarcoma viral oncogene homolog B1, is a member of the RAF family. BRAF is one of the key factors in mitogen-activated protein kinase (MAPK) signaling pathway, which is activated by members of the Ras family upon growth factor-induced stimulation. BRAF controls and regulates numerous essential cellular mechanisms including cell proliferation, differentiation, development, survival, apoptosis and secretion.1-2 In contrast to the majority of oncogenic fusion kinases such as ALK, ROS1, NTRK1 and RET that are receptor tyrosine kinases, BRAF encodes a non-receptor serine/threonine kinase, placing its normal protein localization within the cytoplasm rather than associated with the plasma membrane.3
BRAF is mutated at a high frequency in several cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, nonsmall cell lung carcinoma, and adenocarcinoma of lung.

Especificidad

Anti-BRAF (V600E) recognizes V600E mutated human BRAF protein. The antibody may be used in various immunochemical techniques including Immunoblotting.

Inmunógeno

Synthetic peptide from the C-terminal region of human BRAF protein, conjugated to KLH

Aplicación

Immunoblotting: a working concentration of 2-4 g/mL is recommended using extract of human HEK-293T cells over-expressing BRAF mutant (V600E) protein.

Forma física

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Código de clase de almacenamiento

10 - Combustible liquids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
077M4858V
51170502

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Nourah Mohammad Obaid et al.
International journal of molecular sciences, 18(3) (2017-03-12)
The development of resistance to previously effective treatments has been a challenge for health care providers and a fear for patients undergoing cancer therapy. This is an unfortunately frequent occurrence for patients undergoing targeted therapy for tumours harboring the activating
Roland Houben et al.
Journal of carcinogenesis, 3, 6-6 (2004-03-30)
Genes of the Raf family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Recently, it was shown that activating mutations of BRaf are found with high frequency in human melanomas. The Ras family member
Nicolas Stransky et al.
Nature communications, 5, 4846-4846 (2014-09-11)
Human cancer genomes harbour a variety of alterations leading to the deregulation of key pathways in tumour cells. The genomic characterization of tumours has uncovered numerous genes recurrently mutated, deleted or amplified, but gene fusions have not been characterized as
Alexandra Thiel et al.
Frontiers in oncology, 3, 281-281 (2013-12-04)
Different genetic aberrations of BRAF have been reported in various malignancies. BRAF is member of the RAS/RAF/MEK/ERK pathway and constitutive activity of this pathway can lead to increased cellular growth, invasion, and metastasis. The most common activating BRAF mutation in
Sara C Shalin
Laboratory investigation; a journal of technical methods and pathology, 97(2), 158-165 (2016-11-29)
Translocations resulting in a kinase fusion are well reported in many tumor types and indeed can be defining, particularly in the case of hematopoietic malignancies. The recent reports of multiple protein kinase fusions within melanocytic neoplasms, particularly in those with
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico